The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The OCREVUS Co-pay Program may help eligible commercially insured patients who have been prescribed OCREVUS with their drug costs, infusion costs or both.
Help with drug costs
Help with infusion costs
*Depending on how the health insurance plan applies manufacturer co-pay assistance for out-of-pocket costs or if they match the maximum benefit of the program, patients may owe more than $5.
†Your patients may be able to use the OCREVUS Co-pay Program for their infusion costs if they are receiving OCREVUS from the Genentech Patient Foundation.
If a patient is not eligible for the OCREVUS Co-pay Program, there may be other options for co-pay assistance. Call (844) OCREVUS (844-627-3887) to speak to a Patient Navigator or visit OCREVUS.com to learn more.
OCREVUS is indicated for the treatment of:
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Infusion reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion
Reduction in Immunoglobulins:
Monitor the level of immunoglobulins at the beginning of treatment. Monitor during and after discontinuation of treatment with OCREVUS, until B-cell repletion, and especially when recurrent serious infections are suspected. Consider discontinuing OCREVUS in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins
Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS
Most Common Adverse Reactions
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions.
PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.
For additional safety information, please see the [accompanying] full Prescribing Information and Medication Guide.